Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
Announces Preliminary 2022 Financial Results GAITHERSBURG, Md. , Jan. 09, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE: EBS) today announced a sharpened strategic focus on protecting and...
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
GAITHERSBURG, Md. , Jan. 05, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity procurement contract...
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
Emergent’s supplemental new drug application is the first prescription-to-over-the-counter switch application in history to be granted Priority Review by the FDA. NARCAN ® (naloxone HCI) Nasal...
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies GAITHERSBURG, Md. , Nov. 14, 2022 (GLOBE...
Emergent BioSolutions Reports Financial Results For Third Quarter 2022
GAITHERSBURG, Md. , Nov. 08, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2022 . “For more...
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
GAITHERSBURG, Md. , Nov. 01, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced results from a Phase 2 study evaluating the safety and immunogenicity of the company’s...
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
GAITHERSBURG, Md. , Oct. 18, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, November 8, 2022 , at 5:00 pm eastern time to discuss the...
Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
GAITHERSBURG, Md. , Sept. 26, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of exclusive worldwide rights to TEMBEXA ®...
Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate
GAITHERSBURG, Md. , Sept. 06, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety...
Emergent BioSolutions Reports Financial Results for Second Quarter 2022
Reports strong core products segment performance offset by impact of continuing post-COVID transition and re-baselining of CDMO services segment Resumes financial guidance; provides update to full...
Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022
GAITHERSBURG, Md. , July 18, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, August 1, 2022 , at 5:00 pm eastern time to discuss the...
Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola
GAITHERSBURG, Md. and MIAMI , July 07, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement with Ridgeback Biotherapeutics...